MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.85 EUR | +0.15% |
|
+0.22% | +99.56% |
| 11/04 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
| 11/04 | Trending : Novartis Begins Tender Offer for MorphoSys Shares | DJ |
| Sales 2024 * | 252M 269M 22.43B | Sales 2025 * | 325M 347M 28.98B | Capitalization | 2.56B 2.73B 228B |
|---|---|---|---|---|---|
| Net income 2024 * | -182M -195M -16.23B | Net income 2025 * | -115M -123M -10.26B | EV / Sales 2024 * | 9.74 x |
| Net cash position 2024 * | 106M 113M 9.45B | Net cash position 2025 * | 241M 257M 21.45B | EV / Sales 2025 * | 7.12 x |
| P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-32.9
x | Employees | 524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More recommendations
More press releases
More news
| 1 day | +0.15% | ||
| 1 week | +0.22% | ||
| Current month | +0.97% | ||
| 1 month | +0.94% | ||
| 3 months | +66.01% | ||
| 6 months | +136.25% | ||
| Current year | +99.56% |
1 week
67.70
67.90
1 month
66.8568.00
Current year
29.7368.00
1 year
14.5268.00
3 years
11.8180.14
5 years
11.81146.30
10 years
11.81146.30
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 01/19/01 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 07/23/07 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 17/18/17 |
| Director/Board Member | 67 | 17/18/17 | |
Marc Cluzel
CHM | Chairman | 69 | 31/12/31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.44% | 125 M€ | -.--% | ||
| 0.80% | 17 M€ | -.--% | - | |
| 0.11% | 2 M€ | -.--% | ||
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 67.85 | +0.15% | 39,191 |
| 25/24/25 | 67.75 | +0.07% | 56,527 |
| 24/24/24 | 67.7 | -0.07% | 63,222 |
| 23/24/23 | 67.75 | 0.00% | 55,900 |
| 22/24/22 | 67.75 | +0.07% | 131,745 |
Delayed Quote Xetra, April 26, 2024 at 09:06 pm IST
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
29/04/2024
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
67.85
EUR
Average target price
58.71
EUR
Spread / Average Target
-13.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +99.56% | 2.73B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MOR Stock
